Dermapharm Holding SECHIX:DMPD 80 5-Year Yield-on-Cost % is 1.87 as of Jul. 02, 2026, which is 18% below its 10-year median of 2.27. GuruFocus rates CHIX:DMPD with a GF Score™ of 80/100 and a GF Value™ of €38.34. The stock has 9 warning signs investors should review. Among 516 Drug Manufacturers companies, Dermapharm Holding SE ranks worse than 57.56% on this metric.
Dermapharm Holding SE's yield on cost for the quarter that ended in Mar. 2026 was 1.87.
The historical rank and industry rank for Dermapharm Holding SE's 5-Year Yield-on-Cost % or its related term are showing as below:
CHIX:DMPd'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.97 Med: 2.27 Max: 5.9
Current: 1.87
During the past 13 years, Dermapharm Holding SE's highest Yield on Cost was 5.90. The lowest was 0.97. And the median was 2.27.
CHIX:DMPd's 5-Year Yield-on-Cost % is ranked worse than 57.56% of 516
companies
in the Drug Manufacturers industry
Industry Median: 2.345
vs CHIX:DMPd: 1.87
Dermapharm Holding SE (CHIX:DMPd) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Dermapharm Holding SE 5-Year Yield-on-Cost % Related Terms
CHIX:DMPD vs ZTS, UTHR, VTRS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dermapharm Holding SE 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Dermapharm Holding SE's 5-Year Yield-on-Cost % falls into.
Dermapharm Holding SE 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Dermapharm Holding SE (CHIX:DMPD) has a 5-Year Yield-on-Cost % of 1.87 as of Jul. 02, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Dermapharm Holding SE and its competitors. This is 18% below median its historical median of 2.27. Over the past decade, Dermapharm Holding SE's 5-Year Yield-on-Cost % has ranged from 0.97 to 5.90. According to the industry distribution chart, Dermapharm Holding SE ranks #297 out of 516 companies in the Drug Manufacturers industry, placing it in the top 57.6%.
Is Dermapharm Holding SE's 5-Year Yield-on-Cost % too high?
Dermapharm Holding SE's current 5-Year Yield-on-Cost % of 1.87 is 18% below median its 10-year median of 2.27. Over the past 10 years, this metric has ranged from a low of 0.97 to a high of 5.90. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.35. Dermapharm Holding SE's value of 1.87 is 20.3% below this industry median. Based on the distribution chart, Dermapharm Holding SE ranks #297 out of 516 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Dermapharm Holding SE has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Dermapharm Holding SE's 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Dermapharm Holding SE ranks #297 out of 516 companies for 5-Year Yield-on-Cost %. This places Dermapharm Holding SE in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.35. Dermapharm Holding SE's value of 1.87 is 20.3% below this benchmark. Historically, Dermapharm Holding SE's own 5-Year Yield-on-Cost % has ranged from 0.97 to 5.90 over the past decade. While the company's 10-year median is 2.27 vs. the industry median of 2.35, Dermapharm Holding SE has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.35, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dermapharm Holding SE's current 5-Year Yield-on-Cost % of 1.87 is 20.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Dermapharm Holding SE and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dermapharm Holding SE's current 5-Year Yield-on-Cost % is 1.87, which is 18% below median its own 10-year median of 2.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dermapharm Holding SE stock overvalued right now?
Dermapharm Holding SE (CHIX:DMPD) has a current 5-Year Yield-on-Cost % of 1.87. The stock's GF Value™ is €38.34, compared to a current price of €46.18 — trading 20.4% above its estimated fair value. The current 5-Year Yield-on-Cost % is 1.87, which is 18% below median its 10-year median of 2.27 and 20.3% below the Drug Manufacturers industry median of 2.35. Dermapharm Holding SE's overall GF Score™ is 80/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Dermapharm Holding SE (CHIX:DMPD), the current 5-Year Yield-on-Cost % is 1.87 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dermapharm Holding SE (CHIX:DMPD) Overvalued in 2026?
Based on GuruFocus' analysis, Dermapharm Holding SE stock appears to be overvalued.
The current stock price of €46.18 is trading 20.4% above its estimated GF Value™ of €38.34.
Key valuation signals for CHIX:DMPD:
5-Year Yield-on-Cost %: 1.87 (18% below median its 10-year median of 2.27)
GF Value™: €38.34 vs. price of €46.18 (20.4% above fair value)
Industry Position: 20.3% below the Drug Manufacturers median (#297 of 516)
No single metric tells the full story. See the CHIX:DMPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
80GF Score
Get the complete analysis for CHIX:DMPD
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DMPD has been successfully added to your 